Elagolix sodium was approved by FDA in July 2018 for
**Core Concept**
Elagolix sodium is a selective, reversible inhibitor of the human gonadotropin-releasing hormone (GnRH) receptor, which plays a key role in regulating the reproductive axis. The GnRH receptor is responsible for stimulating the release of gonadotropins (LH and FSH) from the anterior pituitary gland, leading to the production of sex hormones.
**Why the Correct Answer is Right**
Elagolix sodium works by competitively inhibiting the GnRH receptor, thereby reducing the production of gonadotropins and subsequently decreasing the levels of sex hormones, such as estrogen and testosterone. This mechanism is particularly useful in treating conditions associated with excessive sex hormone production, such as endometriosis and uterine fibroids. The FDA approval of elagolix sodium in July 2018 was specifically for the treatment of moderate to severe pain associated with endometriosis.
**Why Each Wrong Option is Incorrect**
**Option A:** Elagolix sodium is not primarily used for treating conditions associated with low sex hormone production, such as hypogonadism.
**Option B:** Although elagolix sodium does affect gonadotropin release, it is not primarily used for treating conditions associated with abnormal gonadotropin secretion, such as precocious puberty.
**Option C:** Elagolix sodium is not a selective estrogen receptor modulator (SERM) and does not have a primary mechanism of action through estrogen receptor antagonism.
**Clinical Pearl / High-Yield Fact**
Elagolix sodium is an example of a medication that targets the reproductive axis, highlighting the importance of the GnRH receptor in regulating sex hormone production and the potential therapeutic benefits of modulating this axis in various gynecological conditions.
**Correct Answer:** C.